chartexchange

NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma

GlobeNewswire Inc. | Oct 24, 2026 7:00 AM EDT

Data presented at the 2026 Congress of the European Society for Medical Oncology

Read original article